Dec 18, 2025, 08:00 ET CagriSema 2.4 mg/2.4 mg is an investigational fixed-dose injectable medicine that combines the novel amylin analogue, cagrilintide, with semaglutide to target complementary obesity-related pathways 1,2 In the REDEFINE 1 phase 3 trial, adults with obesity, or overweight with at least one obesity-related complication, taking CagriSema lost an average of 23% body weight when evaluating the treatment effect if all patients stayed on treatment *2 Novo Nordisk continues to build on its 100-year-plus legacy of science and innovation, with potential new treatments in obesity PLAINSBORO, N.J
C., Ookhtens, M
Animal studies, as highlighted by Ooyama et al
The decision depends on your labs, symptoms, age, fertility goals, cardiovascular risk, metabolic health, and treatment history
Ferroptosis: A regulated cell death Nexus linking metabolism, redox biology, and disease
Vitamin D and calcium regulation of epidermal wound healing